Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Sells $240M in Senior Notes

NEW YORK (GenomeWeb News) – Bruker has sold $240 million worth of senior notes through a private placement, it said in a filing with the US Securities and Exchange Commission Thursday.

The firm sold four series of notes in the placement: $20 million of 3.16 percent Series 2012A Senior Notes, Tranche A, due Jan. 18, 2017; $15 million of 3.74 percent Series 2012A Senior Notes, Tranche B, due Jan. 18, 2019; $105 million of 4.31 percent Series 2012A Senior Notes, Tranche C, due Jan. 18, 2022; and $100 million of 4.46 percent Series 2012A Senior Notes, Tranche D, due Jan. 18, 2024.

Bruker noted that under the terms of the note purchase agreement it may sell additional senior notes up to an aggregate amount of $600 million.

It intends to use the proceeds to reduce outstanding debt under its revolving credit facilities and for general corporate purposes.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.